Adverse Effects Secondary to Baclofen Withdrawal
Drug Intelligence & Clinical Pharmacy · 1985-04 · 19 (4) · 304-306
DOI: 10.1177/106002808501900415 ↗Kurz gefasst
Fallbericht in der Zeitschrift Drug Intelligence & Clinical Pharmacy, online erschienen am 05.12.2017. Verfasst von S M Garabedian-Ruffalo und 1 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Drug therapy is now the preferred method of treatment for spasticity, and several effective agents have been developed. The safety and efficacy of these drugs has been established in short-term studies. Overall, due to its low incidence of sedation and serious side effects, baclofen appears to be the drug of choice in the treatment of spinal cord-related spasticity. It is, however, not without its side effects due to both its administration and abrupt withdrawal. This case illustrates some significant problems associated with the abrupt withdrawal of long-term baclofen therapy in a patient with multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Garabedian-Ruffalo, S. M., & Ruffalo, R. L. (1985). Adverse Effects Secondary to Baclofen Withdrawal. Drug Intelligence & Clinical Pharmacy, 19(4), 304-306. https://doi.org/10.1177/106002808501900415
Vancouver
Garabedian-Ruffalo SM, Ruffalo RL. Adverse Effects Secondary to Baclofen Withdrawal. Drug Intelligence & Clinical Pharmacy. 1985;19(4):304-306. doi:10.1177/106002808501900415
BibTeX
@article{GarabedianRuffalo1985,
author = {Garabedian-Ruffalo, S M and Ruffalo, R L},
title = {Adverse Effects Secondary to Baclofen Withdrawal},
journal = {Drug Intelligence & Clinical Pharmacy},
year = {1985},
volume = {19},
number = {4},
pages = {304--306},
doi = {10.1177/106002808501900415}
}
EUVIMED